文献速递流行病学与生物统计真实世界研究与卫生经济

基于真实世界数据对2型糖尿病治疗药物心血管结局试验进行目标试验模拟:观察性研究的系统综述

Target trial emulation of cardiovascular outcome trials of medications used to treat type 2 diabetes using real-world data: a systematic review of observational studies.
PubMed 文献 · J Clin Epidemiol · 2025-06-21

该系统综述纳入19项观察性研究,包括4项目标试验模拟的队列研究和15项评估试验入选比例的横断面研究。结果显示,对于二肽基肽酶-4抑制剂、胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白-2抑制剂,随机对照试验与真实世界数据在非劣效性结论上一致,但试验入选比例中位数范围分别为13%至31%和12%至43%,提示试验缺乏代表性。

要点

  • 随机对照试验与真实世界数据在心血管结局的非劣效性结论上一致。
  • 钠-葡萄糖协同转运蛋白-2抑制剂试验入选比例中位数为13%至31%。
  • 胰高血糖素样肽-1受体激动剂试验入选比例中位数为12%至43%。

核心结论

  • 结果表明,随机对照试验与真实世界数据的估计值一致,但试验缺乏代表性。
  • 需要更多关于使用真实世界数据模拟心血管结局试验的研究,以理解不同模拟方法可能如何影响结果。

研究设计与样本

  • 系统综述,检索MEDLINE、EMBASE和Cochrane数据库,纳入针对二肽基肽酶-4抑制剂、胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白-2抑制剂的观察性研究。
  • 共纳入19项研究,包括4项对既往随机对照试验进行目标试验模拟的队列研究和15项评估试验入选比例的横断面研究。

主要发现

  • 随机对照试验与真实世界数据在所有药物类别中均发现非劣效性,结果一致。
  • 钠-葡萄糖协同转运蛋白-2抑制剂试验的入选比例中位数范围为13%至31%。
  • 胰高血糖素样肽-1受体激动剂试验的入选比例中位数范围为12%至43%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Cardiovascular outcome trials are mandated by the US Food and Drug Administration to assess the cardiovascular safety of new antidiabetic medications before entering the market. However, these trials often involve highly selective populations and results may not generalize to routine practice. METHODS: Our study aimed to synthesize observational studies to assess the generalizability of cardiovascular outcome trials to routine practice. We systematically reviewed observational studies that were target trial emulations of previous cardiovascular outcome trials for dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, and sodium glucose cotransporter-2 (SGLT-2) inhibitors among patients with type 2 diabetes. We searched the MEDLINE, EMBASE, and Cochrane databases for observational studies that focused on trial emulation or cross-sectional studies that reported the proportion of real-world patients eligible for completed trials. RESULTS: Nineteen studies were included in our systematic review, including four cohort studies that were target trial emulations of previous randomized controlled trials (RCTs) and 15 cross-sectional studies that evaluated trial eligibility. Results between RCTs and real-world data (RWD) were concordant for all drug classes in finding noninferiority. The median eligibility percentage ranged from 13% to 31% for SGLT-2 inhibitor trials and 12% to 43% for GLP-1 receptor agonist trials. CONCLUSION: These results suggest that, while RCTs and RWD are concordant in their estimates, the trials lack representativeness. More research is needed on the emulation of cardiovascular outcome trials using RWD to understand how different emulation methods may impact findings.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Wang W, Tang WC, Webster-Clark M, et al. Target trial emulation of cardiovascular outcome trials of medications used to treat type 2 diabetes using real-world data: a systematic review of observational studies. J Clin Epidemiol. 2025. PMID: 40550404. doi:10.1016/j.jclinepi.2025.111872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。